Jacobs & Co. CA Sells 784 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Jacobs & Co. CA reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.9% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 26,537 shares of the biopharmaceutical company’s stock after selling 784 shares during the quarter. Jacobs & Co. CA’s holdings in Gilead Sciences were worth $2,149,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cetera Investment Advisers lifted its holdings in Gilead Sciences by 9.2% during the first quarter. Cetera Investment Advisers now owns 57,967 shares of the biopharmaceutical company’s stock valued at $3,446,000 after purchasing an additional 4,877 shares during the last quarter. Baird Financial Group Inc. lifted its holdings in shares of Gilead Sciences by 3.9% in the first quarter. Baird Financial Group Inc. now owns 448,409 shares of the biopharmaceutical company’s stock worth $26,660,000 after buying an additional 16,643 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in shares of Gilead Sciences by 44.3% in the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 8,642 shares of the biopharmaceutical company’s stock worth $514,000 after buying an additional 2,654 shares in the last quarter. Donaldson Capital Management LLC lifted its holdings in shares of Gilead Sciences by 12.5% in the first quarter. Donaldson Capital Management LLC now owns 5,763 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 641 shares in the last quarter. Finally, Ergoteles LLC bought a new position in shares of Gilead Sciences in the first quarter worth approximately $2,304,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $73.01 on Thursday. The business’s 50 day moving average price is $75.38 and its 200-day moving average price is $77.32. The company has a market cap of $90.90 billion, a P/E ratio of 16.22, a P/E/G ratio of 0.92 and a beta of 0.18. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. Gilead Sciences, Inc. has a fifty-two week low of $71.37 and a fifty-two week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). The business had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The business’s revenue was down 3.7% compared to the same quarter last year. During the same period last year, the company earned $1.67 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.07 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be given a dividend of $0.77 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.22%. Gilead Sciences’s dividend payout ratio is presently 68.44%.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Cantor Fitzgerald reduced their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. Wells Fargo & Company lowered their price objective on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research report on Monday, March 4th. Oppenheimer lowered their price objective on Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, February 12th. Royal Bank of Canada lowered their price target on Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 14th. Finally, Barclays reduced their price objective on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a report on Monday, February 12th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $85.36.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the completion of the sale, the insider now directly owns 100,936 shares in the company, valued at approximately $7,386,496.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Gilead Sciences news, insider Johanna Mercier sold 8,242 shares of the stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $85.23, for a total value of $702,465.66. Following the completion of the sale, the insider now directly owns 82,729 shares in the company, valued at $7,050,992.67. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the transaction, the insider now directly owns 100,936 shares in the company, valued at $7,386,496.48. The disclosure for this sale can be found here. Insiders sold 15,242 shares of company stock worth $1,277,726 in the last three months. 0.16% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.